Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC

Clinical trial NCT07641023 · RECRUITING

Trial details

NCT number: NCT07641023
Sponsor: Beijing Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer Advanced/Metastatic

Start date: 2026-03-02
Primary completion: 2027-03-14
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.